Clinical

Dataset Information

0

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)


ABSTRACT: The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.

DISEASE(S): Metastatic Colorectal Cancer,Microsatellite Instability,Microsatellite Instability High (msi-h) Or Mismatch Repair Deficientmetastatic Colorectal Cancer (dmmr),Colorectal Neoplasms,Microsatellite Instability High (msi-h) Or Mismatch Repair Deficient metastatic Colorectal Cancer (dmmr)

PROVIDER: 2310012 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
| 2717352 | ecrin-mdr-crc
2023-06-01 | GSE210018 | GEO
2023-06-01 | GSE211221 | GEO
| 2365524 | ecrin-mdr-crc
2024-11-26 | GSE264586 | GEO
2024-10-24 | GSE268364 | GEO
| 2718797 | ecrin-mdr-crc
2024-01-09 | GSE234136 | GEO
2021-04-07 | GSE149206 | GEO